Protective role of soluble receptor for advanced glycation end-products in patients with non-alcoholic fatty liver disease

Digestive and Liver Disease

Volumn 49, Issue 5, 2017, Pages 523-529

  Zelber Sagi, Shira ^a,b   Salomone, Federico ^c   Kolodkin Gal, Ilana ^d   Erez, Noam ^a   Buch, Assaf ^a,e   Yeshua, Hanny ^a,e   Webb, Muriel ^a,e   Halpern, Zamir ^a,e   Shibolet, Oren ^a,e  

^a TEL AVIV SOURASKY MEDICAL CENTER   (Israel)

^b UNIVERSITY OF HAIFA   (Israel)

^c Acireale Hospital   (Italy)

^d WEIZMANN INSTITUTE OF SCIENCE   (Israel)

^e TEL AVIV UNIVERSITY   (Israel)

Author keywords

Diet; Hepato renal index; Lifestyle; NAFLD fibrosis score; N (Carboxymethyl) lysine

Indexed keywords

6 N CARBOXYMETHYLLYSINE; ADVANCED GLYCATION END PRODUCT RECEPTOR; ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; FERRITIN; GAMMA GLUTAMYLTRANSFERASE; GLUCOSE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN; INSULIN; URIC ACID; BIOLOGICAL MARKER; LYSINE; N(6)-CARBOXYMETHYLLYSINE;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; AMINO ACID BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BODY MASS; CALORIC INTAKE; CARBOHYDRATE INTAKE; COHORT ANALYSIS; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DIETARY INTAKE; DIGESTIVE SYSTEM DISEASE ASSESSMENT; DISEASE ASSOCIATION; FEMALE; FERRITIN BLOOD LEVEL; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; GLUCOSE BLOOD LEVEL; HEMOGLOBIN BLOOD LEVEL; HUMAN; HUMAN TISSUE; INSULIN BLOOD LEVEL; LIFESTYLE MODIFICATION; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; NONALCOHOLIC FATTY LIVER; NONALCOHOLIC FATTY LIVER DISEASE FIBROSIS SCORE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN INTAKE; URIC ACID BLOOD LEVEL; WAIST CIRCUMFERENCE; ANALOGS AND DERIVATIVES; BLOOD; CASE CONTROL STUDY; ISRAEL; LIFESTYLE; MIDDLE AGED; MULTIVARIATE ANALYSIS; QUESTIONNAIRE; SOLUBILITY; STATISTICAL MODEL;

ADULT; BIOMARKERS; CASE-CONTROL STUDIES; FEMALE; HUMANS; ISRAEL; LIFE STYLE; LOGISTIC MODELS; LYSINE; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NON-ALCOHOLIC FATTY LIVER DISEASE; RECEPTOR FOR ADVANCED GLYCATION END PRODUCTS; SOLUBILITY; SURVEYS AND QUESTIONNAIRES;

EID: 85011629893     PISSN: 15908658     EISSN: 18783562     Source Type: Journal    
DOI: 10.1016/j.dld.2017.01.148     Document Type: Article

References (51)

1. [1] Loomba, R., Sanyal, A.J., The global NAFLD epidemic. Nature Reviews Gastroenterology & Hepatology 10 (2013), 686–690.
2. [2] Zelber-Sagi, S., Ratziu, V., Oren, R., Nutrition and physical activity in NAFLD: an overview of the epidemiological evidence. World Journal of Gastroenterology 17 (2011), 3377–3389.
3. [3] Dongiovanni, P., Romeo, S., Valenti, L., Genetic factors in the pathogenesis of nonalcoholic fatty liver and steatohepatitis. BioMed Research International, 2015, 2015, 460190.
4. [4] Berlanga, A., Guiu-Jurado, E., Porras, J.A., et al. Molecular pathways in non-alcoholic fatty liver disease. Clinical and Experimental Gastroenterology 7 (2014), 221–239.
5. [5] Sung, K.C., Kim, S.H., Interrelationship between fatty liver and insulin resistance in the development of type 2 diabetes. The Journal of Clinical Endocrinology and Metabolism 96 (2011), 1093–1097.
6. [6] Yamada, T., Fukatsu, M., Suzuki, S., et al. Fatty liver predicts impaired fasting glucose and type 2 diabetes mellitus in Japanese undergoing a health checkup. Journal of Gastroenterology and Hepatology 25 (2010), 352–356.
7. [7] Sung, K.C., Jeong, W.S., Wild, S.H., et al. Combined influence of insulin resistance, overweight/obesity, and fatty liver as risk factors for type 2 diabetes. Diabetes Care 35 (2012), 717–722.
8. [8] Zelber-Sagi, S., Lotan, R., Shibolet, O., et al. Non-alcoholic fatty liver disease independently predicts prediabetes during a 7-year prospective follow-up. Liver International 33 (2013), 1406–1412.
9. [9] Lonardo, A., Ballestri, S., Marchesini, G., et al. Nonalcoholic fatty liver disease: a precursor of the metabolic syndrome. Digestive and Liver Disease 47 (2015), 181–190.
10. [10] Zhang, Y., Zhang, T., Zhang, C., et al. Identification of reciprocal causality between non-alcoholic fatty liver disease and metabolic syndrome by a simplified Bayesian network in a Chinese population. BMJ Open, 5, 2015, e008204.
11. [11] Lonardo, A., Sookoian, S., Pirola, C.J., et al. Non-alcoholic fatty liver disease and risk of cardiovascular disease. Metabolism 65 (2016), 1136–1150.
12. [12] Lonardo, A., Sookoian, S., Chonchol, M., et al. Cardiovascular and systemic risk in nonalcoholic fatty liver disease—atherosclerosis as a major player in the natural course of NAFLD. Current Pharmaceutical Design 19 (2013), 5177–5192.
13. [13] Yamagishi, S., Maeda, S., Matsui, T., et al. Role of advanced glycation end products (AGEs) and oxidative stress in vascular complications in diabetes. Biochimica et Biophysica Acta 1820 (2012), 663–671.
14. [14] Pertynska-Marczewska, M., Merhi, Z., Relationship of advanced glycation end products with cardiovascular disease in menopausal women. Reproductive Sciences 22 (2015), 774–782.
15. [15] Moy, K.A., Jiao, L., Freedman, N.D., et al. Soluble receptor for advanced glycation end products and risk of liver cancer. Hepatology 57 (2013), 2338–2345.
16. [16] Ramasamy, R., Yan, S.F., Schmidt, A.M., Advanced glycation endproducts: from precursors to RAGE: round and round we go. Amino Acids 42 (2012), 1151–1161.
17. [17] Jiao, L., Taylor, P.R., Weinstein, S.J., et al. Advanced glycation end products, soluble receptor for advanced glycation end products, and risk of colorectal cancer. Cancer Epidemiology Biomarkers and Prevention 20 (2011), 1430–1438.
18. [18] Uribarri, J., Del Castillo, M.D., de la Maza, M.P., et al. Dietary advanced glycation end products and their role in health and disease. Advances in Nutrition 6 (2015), 461–473.
19. [19] Cerami, C., Founds, H., Nicholl, I., et al. Tobacco smoke is a source of toxic reactive glycation products. Proceedings of the National Academy of Sciences of the United States of America 94 (1997), 13915–13920.
20. [20] Schmidt, A.M., Soluble RAGEs—prospects for treating & tracking metabolic and inflammatory disease. Vascular Pharmacology 72 (2015), 1–8.
21. [21] Zelber-Sagi, S., Buch, A., Yeshua, H., et al. Effect of resistance training on non-alcoholic fatty-liver disease a randomized-clinical trial. World Journal of Gastroenterology 20 (2014), 4382–4392.
22. [22] American College of Sports Medicine Position Stand, Progression models in resistance training for healthy adults. Medicine and Science in Sports and Exercise 41 (2009), 687–708.
23. [23] American College of Sports Medicine Position Stand, The recommended quantity and quality of exercise for developing and maintaining cardiorespiratory and muscular fitness, and flexibility in healthy adults. Medicine and Science in Sports and Exercise 30 (1998), 975–991.
24. [24] Keinan-Boker, L., Noyman, N., Chinich, A., et al. Overweight and obesity prevalence in Israel: findings of the first national health and nutrition survey (MABAT). Israel Medical Association Journal 7 (2005), 219–223.
25. [25] Chalasani, N., Younossi, Z., Lavine, J.E., et al. The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. Hepatology 55 (2012), 2005–2023.
26. [26] Going, S.B., Massett, M.P., Hall, M.C., et al. Detection of small changes in body composition by dual-energy X-ray absorptiometry. American Journal of Clinical Nutrition 57 (1993), 845–850.
27. [27] Haarbo, J., Gotfredsen, A., Hassager, C., et al. Validation of body composition by dual energy X-ray absorptiometry (DEXA). Clinical Physiology 11 (1991), 331–341.
28. [28] Zelber-Sagi, S., Nitzan-Kaluski, D., Goldsmith, R., et al. Long term nutritional intake and the risk for non-alcoholic fatty liver disease (NAFLD): a population based study. Journal of Hepatology 47 (2007), 711–717.
29. [29] Zelber-Sagi, S., Nitzan-Kaluski, D., Goldsmith, R., et al. Role of leisure-time physical activity in nonalcoholic fatty liver disease: a population-based study. Hepatology 48 (2008), 1791–1798.
30. [30] Zelber-Sagi, S., Nitzan-Kaluski, D., Halpern, Z., et al. NAFLD and hyperinsulinemia are major determinants of serum ferritin levels. Journal of Hepatology 46 (2007), 700–707.
31. [31] Gore, R., Diffuse liver disease. Gore, R.L.M., Laufer, I., et al. (eds.) Textbook of gastrointestinal radiology, 1994, Saunders, Philadelphia, 1968–2017.
32. [32] Zelber-Sagi, S., Nitzan-Kaluski, D., Halpern, Z., et al. Prevalence of primary non-alcoholic fatty liver disease in a population-based study and its association with biochemical and anthropometric measures. Liver International 26 (2006), 856–863.
33. [33] Webb, M., Yeshua, H., Zelber-Sagi, S., et al. Diagnostic value of a computerized hepatorenal index for sonographic quantification of liver steatosis. American Journal of Roentgenology 192 (2009), 909–914.
34. [34] Angulo, P., Hui, J.M., Marchesini, G., et al. The NAFLD fibrosis score: a noninvasive system that identifies liver fibrosis in patients with NAFLD. Hepatology 45 (2007), 846–854.
35. [35] Kajikawa, M., Nakashima, A., Fujimura, N., et al. Ratio of serum levels of AGEs to soluble form of RAGE is a predictor of endothelial function. Diabetes Care 38 (2015), 119–125.
36. [36] Salomone, F., Godos, J., Zelber-Sagi, S., Natural antioxidants for non-alcoholic fatty liver disease: molecular targets and clinical perspectives. Liver International 36 (2016), 5–20.
37. [37] Basta, G., Sironi, A.M., Lazzerini, G., et al. Circulating soluble receptor for advanced glycation end products is inversely associated with glycemic control and S100A12 protein. The Journal of Clinical Endocrinology and Metabolism 91 (2006), 4628–4634.
38. [38] Devangelio, E., Santilli, F., Formoso, G., et al. Soluble RAGE in type 2 diabetes: association with oxidative stress. Free Radical Biology & Medicine 43 (2007), 511–518.
39. [39] Huang, M., Que, Y., Shen, X., Correlation of the plasma levels of soluble RAGE and endogenous secretory RAGE with oxidative stress in pre-diabetic patients. Journal of Diabetes and Its Complications 29 (2015), 422–426.
40. [40] Oz Gul, O., Tuncel, E., Yilmaz, Y., et al. Comparative effects of pioglitazone and rosiglitazone on plasma levels of soluble receptor for advanced glycation end products in type 2 diabetes mellitus patients. Metabolism 59 (2010), 64–69.
41. [41] Choi, K.M., Han, K.A., Ahn, H.J., et al. Effects of exercise on sRAGE levels and cardiometabolic risk factors in patients with type 2 diabetes: a randomized controlled trial. The Journal of Clinical Endocrinology and Metabolism 97 (2012), 3751–3758.
42. [42] Hagen, I., Schulte, D.M., Muller, N., et al. Soluble receptor for advanced glycation end products as a potential biomarker to predict weight loss and improvement of insulin sensitivity by a very low calorie diet of obese human subjects. Cytokine 73 (2015), 265–269.
43. [43] Yilmaz, Y., Ulukaya, E., Gul, O.O., et al. Decreased plasma levels of soluble receptor for advanced glycation endproducts (sRAGE) in patients with nonalcoholic fatty liver disease. Clinical Biochemistry 42 (2009), 802–807.
44. [44] D'Adamo, E., Giannini, C., Chiavaroli, V., et al. What is the significance of soluble and endogenous secretory receptor for advanced glycation end products in liver steatosis in obese prepubertal children. Antioxidants Redox Signaling 14 (2011), 1167–1172.
45. [45] Yonekura, H., Yamamoto, Y., Sakurai, S., et al. Novel splice variants of the receptor for advanced glycation end-products expressed in human vascular endothelial cells and pericytes, and their putative roles in diabetes-induced vascular injury. Biochemical Journal 370 (2003), 1097–1109.
46. [46] Basta, G., Lazzerini, G., Massaro, M., et al. Advanced glycation end products activate endothelium through signal-transduction receptor RAGE: a mechanism for amplification of inflammatory responses. Circulation 105 (2002), 816–822.
47. [47] Neumann, A., Schinzel, R., Palm, D., et al. High molecular weight hyaluronic acid inhibits advanced glycation endproduct-induced NF-kappaB activation and cytokine expression. FEBS Letters 453 (1999), 283–287.
48. [48] Park, L., Raman, K.G., Lee, K.J., et al. Suppression of accelerated diabetic atherosclerosis by the soluble receptor for advanced glycation endproducts. Nature Medicine 4 (1998), 1025–1031.
49. [49] Song, F., Hurtado del Pozo, C., Rosario, R., et al. RAGE regulates the metabolic and inflammatory response to high-fat feeding in mice. Diabetes 63 (2014), 1948–1965.
50. [50] Mahali, S.K., Verma, N., Manna, S.K., Advanced glycation end products induce lipogenesis: regulation by natural xanthone through inhibition of ERK and NF-kappaB. Journal of Cellular Physiology 229 (2014), 1972–1980.
51. [51] Mancini, M., Prinster, A., Annuzzi, G., et al. Sonographic hepatic-renal ratio as indicator of hepatic steatosis: comparison with (1)H magnetic resonance spectroscopy. Metabolism 58 (2009), 1724–1730.